TST 005
Alternative Names: TST-005Latest Information Update: 05 May 2025
At a glance
- Originator Transcenta Holding
- Class Antineoplastics; Immunotherapies; Monoclonal antibodies; Recombinant fusion proteins
- Mechanism of Action Programmed cell death-1 ligand-1 inhibitors; T lymphocyte stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Solid tumours
Most Recent Events
- 05 May 2025 TST 005 is still in phase I trial for Solid tumour (Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China and the US (Transcenta Holding pipeline, May 2025)
- 28 Aug 2024 No recent reports of development identified for phase-I development in Non-small-cell-lung-cancer(Monotherapy) in World (IV)
- 28 Jul 2024 No recent reports of development identified for phase-I development in Solid-tumours(Late-stage disease, Metastatic disease, Monotherapy, Second-line therapy or greater) in China (IV, Infusion)